Connor, Clark & Lunn Investment Management (CC&L)
ZVRA icon

Connor, Clark & Lunn Investment Management (CC&L)’s Zevra Therapeutics ZVRA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.35M Sell
145,222
-6,202
-4% -$55.9K ﹤0.01% 1079
2025
Q4 		$1.36M Buy
151,424
+100,375
+197% +$949K ﹤0.01% 1037
2025
Q3 		$485K Buy
+51,049
New +$512K ﹤0.01% 1267

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ZVRA Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Zevra Therapeutics (ZVRA) stake by 4.1% in Q1 2026, selling an estimated $55.9K and leaving 145,222 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1079.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ZVRA in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.36M in Q4 2025. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 145,222 shares of Zevra Therapeutics worth $1.35M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 6,202 Zevra Therapeutics shares in Q1 2026, an estimated $55.9K.
  • Zevra Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1079 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Zevra Therapeutics position peaked at $1.36M in Q4 2025.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.